Argenx Completes First Safety Study for New Antibody ARGX-213

Argenx (ARGX) announced an update on their ongoing clinical study.

The Phase 1 study “A Study to Assess the Safety of ARGX-213 in Healthy Volunteers” tests a new drug from argenx (ARGX). It aims to confirm basic safety, how the drug moves through the body, and how the immune system responds, giving investors an early read on whether ARGX-213 can support a broader pipeline in immune‑driven diseases.

The trial compares ARGX-213, a lab-made antibody drug, with placebo. It is given by vein or under the skin and is designed to change immune activity in a controlled way, which could later support new treatments in autoimmune or related conditions if safety holds up.

The study is interventional, with volunteers randomly assigned to ARGX-213 or placebo in parallel groups. Both participants and study staff are blinded, meaning no one knows who gets the active drug, and the main goal at this stage is safety, not treatment benefit.

The trial has been marked completed, with volunteers followed for up to about 21 weeks each. The most recent data update was submitted on 22 April 2026, signaling that argenx is refreshing information as it prepares next steps, though no formal study results are posted yet.

For investors, completion of a first-in-human study reduces early development risk and can support sentiment for ARGX by showing steady execution. The update keeps argenx in line with large autoimmune peers that are also advancing early antibody assets, and any clean safety profile could strengthen its position against rivals in targeted immune therapies.

The study is now completed with updated records, and further details are available on the ClinicalTrials portal.

To learn more about ARGX’s potential, visit the Argenx drug pipeline page.